Monthly Archives: September 2014

30 September 2014

Brainomix – University of Oxford Isis Fund I and Parkwalk investment

By |September 30th, 2014|

We have recently closed an investment in Brainomix for the University of Oxford Isis Fund I and Parkwalk Funds.

Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for their patients. Strokes are the third highest cause of death and the primary cause of disability worldwide […]

Oxford PV: WSJ – Perovskite – cheaper solar energy?

By |September 29th, 2014|

Perovskite Offers Shot at Cheaper Solar Energy
Rapid Gains in Efficiency Make This Class of Compounds a Potential Game Changer
A class of compounds first uncovered in the Ural Mountains more than a century ago is now a rock star in the world of solar-energy research.

Meet perovskite, the building block for materials that, as a group, […]

Microsaic Systems – agreement with Gilson Inc

By |September 29th, 2014|

Microsaic Systems Signs Commercial Agreement with Gilson Inc. to Create New Analytical Instruments for the Pharmaceutical and Life Science Industries

29 September 2014: Microsaic Systems plc (AIM: MSYS), the high technology company developing next generation mass spectrometry instruments, is pleased to announce the signing of a commercial agreement with Gilson Inc., a leading international scientific […]

Horizon Discovery – acquires Sage Labs Inc. for $48M

By |September 29th, 2014|

Acquisition makes Horizon the world’s leading gene-editing and translational genomics company
Highlights
·     Horizon acquires Sage Labs Inc. for up to $48M (£29M) comprising up to $16M in cash and up to $32M in new ordinary shares
·     Acquisition creates a fully integrated and world leading translational genomics platform
·     Significantly expands Horizon’s product, service and research offerings providing cost consolidation, and […]

Revolymer – 6 month results

By |September 29th, 2014|

Business Highlights: Consumer Specialties

Revolymer is pleased to have announced, after the period end on 25 September 2014, the signing of its first commercialisation deal in the prioritised Consumer Specialties business area, namely a global licence of its encapsulation polymer technology to the international chemicals group Solvay. The deal is aimed at expanding the commercial applications […]

Tangentix – Follow on Investment

By |September 25th, 2014|

We have recently closed a follow on investment into Tangentix for the Parkwalk Opportunities Fund and a Syndicate.

Tangentix transforms PC gaming by offering free trial, in-game rental and purchase options.

The company’s proprietary algorithms make downloads up to 3x faster, which means that downloads can reach a wider audience, gamers can buy more games, and publishers benefit from […]

Revolymer – signs global licence with Solvay

By |September 25th, 2014|

Revolymer signs global licence to its encapsulation technology with Solvay in the field of PAP products

Revolymer, the British polymer technology company, is delighted to announce that it has signed the first licence in its prioritised Consumer Specialties business area with the international chemicals group Solvay. Under the terms of the deal, Solvay has exclusive […]

Microsaic Systems – signs OEM commercial agreement

By |September 25th, 2014|

Microsaic Systems Signs Commercial Agreement with Leading Global Scientific Company to Create New Analytical Instruments based on ‘Triple Quad’ Technology

25 September 2014: Microsaic Systems plc (AIM: MSYS), the high technology company developing next generation mass spectrometry instruments, is pleased to announce the signing of its first OEM agreement for the development of a chip-based […]

AQDOT – Follow on Investment

By |September 24th, 2014|

We have recently made a follow-on investment into AQDOT on behalf of the University of Cambridge Enterprise Fund II and the Parkwalk UK Technology Fund V.

AQDOT‘s technology allows for an energy- and raw material-efficient way of manufacturing microcapsules, leading to lower energy consumption and less waste.
Potential applications include encapsulating enzymes in laundry detergents, or […]

Surrey NanoSystems – BBC – Vantablack

By |September 23rd, 2014|

How black can black be? See the BBC video here

Horizon Discovery – Interim Results

By |September 23rd, 2014|

Interim Results in-line and Panmure reaffirms ‘Buy Rating’:

Interim Results for the Six Months Ended 30 June 2014

Horizon Reports a Strong First Half Positioning the Company for Continued Growth

Cambridge, UK, 23 September 2014: Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools to organisations engaged in genomics research and the […]

Xeros: Positive update on contracts

By |September 22nd, 2014|

Xeros Technology Group plc (AIM: XSG), the innovative developer of a patented polymer bead laundry cleaning system with multiple identified commercial applications, is pleased to announce that, following its latest cleaning system contract win, it now counts four out of the world’s top five hotel groups* as customers. According to the 2014 World Hotel […]

QS World University Rankings 2014/15

By |September 16th, 2014|

The University of Cambridge and Imperial College surpass Harvard University in the latest QS annual ranking of the world’s top universities, with four British institutions in the top six.

Massachusetts Institute of Technology (MIT) came in at number one, with the University of Cambridge and Imperial College equal second. Harvard cam in at number four and the […]

Oxford PV’s Perovskite Thin-Film Tandem Layer Boosts Solar Cell Performance By 20%

By |September 11th, 2014|

Oxford PV, a developer of innovative technologies and materials for solar applications, has introduced a new application for its thin-film perovskite technology. The breakthrough is designed to boost the conversion efficiency of existing silicon solar cells by 20 percent — the equivalent of a substantial 3 to 5 percent increase in absolute conversion efficiency […]

Oxtex – University of Oxford Isis Fund I investment

By |September 10th, 2014|

We have recently made an investment in Oxtex for the University of Oxford Isis Fund I.

Oxtex has developed a surgical implant device which addresses the problem created by the lack of sufficient skin in areas requiring reconstructive surgery.

Oxtex received the OBN Bioscience award for Best Emerging MedTech in 2011 and Best New Medtech product in 2012.

Oxtex […]

Another Record year for University of Cambridge spin-out investments

By |September 10th, 2014|

The University of Cambridge has broken its early stage investment record for a second year running, approving nine seed fund investments for a total of £2.7 million, an increase on the £2.3 million invested in 2012/13.

“During the past year, returns on investments made by Cambridge Enterprise have gone from strength to strength.”
— Charles Cotton, […]

Clean Air Power – letter of intent signed with global truck manufacturer

By |September 10th, 2014|

Clean Air Power (AIM: CAP), the global leader in the development and delivery of compression-ignited natural gas systems and software for heavy duty vehicles, is pleased to announce that it has signed a Letter of Intent to commence the first phase of a production development program for a MicroPilot diesel-natural gas engine for the […]

Microsaic Systems: partnership with Plexus

By |September 9th, 2014|

Microsaic Systems plc, the developer of chip-based scientific instruments, has entered into an agreement with Plexus.

Under the agreement Plexus will provide manufacturing solutions so that Microsaic’s ability to scale up output rapidly is significantly improved.

Colin Jump, chief executive of Microsaic Systems, added, “Outsourcing the manufacture of the 4000 MiD® has been a key strategic […]

DefiniGEN Joins EBiSC Consortium

By |September 8th, 2014|

DefiniGEN (an investment in the University of Cambridge Enterprise Funds I & II), a leading provider of stem cell life science products and services has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and […]